Skip to main content

Hyperkalemia

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
NCT02033317 | PHASE 2 | INTERVENTIONAL

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

Trial Information
2 Sites
6 Participants
Recruiting
18 Years to 70 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Investigator Site
Orlando,Florida,United States,32809
Investigator Site
Minneapolis,Minnesota,United States,55404

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov